Literature DB >> 17465780

Genzyme: 15 years of cell and gene therapy research.

Caroline De Bie1.   

Abstract

Finding solutions for patients with unmet needs is at the heart of Genzyme's innovative medical research. While small molecules and enzyme-replacement therapies have made significant strides in improving patients' quality of life and expectancy, the solutions to many conditions, such as heart disease or CNS diseases, rely on the capacity of the body to regenerate cells. Cell and gene therapy lend themselves well to providing solutions for these illnesses with no current cure, by harnessing the body's natural ability to heal. Promising research in these fields continues to evolve and constitutes a long-term investment in addressing serious unmet medical needs in various therapeutic areas. Over the past 15 years, Genzyme has established itself as a pioneer in shaping the research and commercial application of cell and gene therapy. Genzyme's first commercially available innovative cell therapies--Carticel and Epicel--have provided a solid foundation to move into new, cutting-edge areas.

Entities:  

Mesh:

Year:  2007        PMID: 17465780     DOI: 10.2217/17460751.2.1.95

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  8 in total

Review 1.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

2.  Natural and Genetically Engineered Proteins for Tissue Engineering.

Authors:  Sílvia Gomes; Isabel B Leonor; João F Mano; Rui L Reis; David L Kaplan
Journal:  Prog Polym Sci       Date:  2012-01-01       Impact factor: 29.190

3.  Bioengineered human vascular networks transplanted into secondary mice reconnect with the host vasculature and re-establish perfusion.

Authors:  Kyu-Tae Kang; Patrick Allen; Joyce Bischoff
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

4.  Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect.

Authors:  M Caminal; D Peris; C Fonseca; J Barrachina; D Codina; R M Rabanal; X Moll; A Morist; F García; J J Cairó; F Gòdia; A Pla; J Vives
Journal:  Cytotechnology       Date:  2015-01-17       Impact factor: 2.058

5.  Fibroblast growth factor-2 facilitates rapid anastomosis formation between bioengineered human vascular networks and living vasculature.

Authors:  Ruei-Zeng Lin; Juan M Melero-Martin
Journal:  Methods       Date:  2012-02-03       Impact factor: 3.608

6.  Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells.

Authors:  Fang Zhang; Dandan Zhang; Kai Cheng; Zaixin Zhou; Shupeng Liu; Liang Chen; Yijun Hu; Chuanbin Mao; Shanrong Liu
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

7.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563

Review 8.  Cell therapy for cartilage repair.

Authors:  Charlotte H Hulme; Jade Perry; Helen S McCarthy; Karina T Wright; Martyn Snow; Claire Mennan; Sally Roberts
Journal:  Emerg Top Life Sci       Date:  2021-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.